UBT251 Injection Phase II Clinical Study (CKD)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.
Also called NCT07134335
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 180 participants
- Registry
-
NCT07134335
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07134335. Randomized; double masking; primary purpose treatment. Start 2025-09-01 (actual); primary completion 2030-07-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- UBT251 Injection Phase II Clinical Study (CKD)
- Condition
- Obesity &Amp; Overweight
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- UBT251
- Intervention (Drug)
- UBT251
- Intervention (Drug)
- UBT251
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Record details
- Record id
cardio:ct-nct07134335- Content hash
f5c5d590052414428e63d33f447f1d1659c7115bcac47695172024abd0b38f46